No price history available.
Key financial summary
Financials in TRY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | TRYm | 1,863 | 2,330 | 4,478 | 11,330 | 15,458 | 19,246 | N/A | N/A |
| Operating profit | TRYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | TRYm | 651 | 1,170 | 1,360 | 3,385 | 69 | -807 | N/A | N/A |
| EPS reported | TRY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | TRY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | TRY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | TRY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | TRYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | TRYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | TRYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | TRY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | TRY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in TRY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Deva Holding A.S. is a Turkish pharmaceutical firm specializing in the development and distribution of a wide array of medicinal goods. Its extensive portfolio encompasses treatments for various conditions, including cancer (antineoplastic agents), immune system disorders (immunomodulating agents), skin ailments (dermatological products), hormonal imbalances (systemic hormonal preparations), and infectious or parasitic diseases (anti-infective and antiparasitic products for systemic use). Additionally, the company offers dietary supplements and electrolyte solutions. Deva Holding also supplies pharmaceuticals targeting major bodily systems such as the urogenital and reproductive systems, blood and hematopoietic organs, the cardiovascular system, musculoskeletal system, nervous system, digestive tract and metabolism, respiratory system, and sensory organs. Furthermore, its offerings include specific drug classes like cephalosporins and penicillin, inhalation therapies, both solid and liquid oncological preparations, and veterinary pharmaceuticals. It also produces active pharmaceutical ingredients (APIs), various sterile dosage forms such as ampoules, liquid and lyophilized vials, and ophthalmic drops, alongside medical ampoules for sterile injectables; cologne is also part of its product line. Beyond its domestic operations, Deva Holding exports its products to approximately 60 nations globally. Established in 1958, the company maintains its headquarters in Istanbul, Turkey, and operates as a subsidiary of Eastpharma S.à R.L.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
Deva Holding A.S. is a Turkish pharmaceutical firm specializing in the development and distribution of a wide array of medicinal goods. Its extensive portfolio encompasses treatments for various conditions, including cancer (antineoplastic agents), immune system disorders (immunomodulating agents), skin ailments (dermatological products), hormonal imbalances (systemic hormonal preparations), and infectious or parasitic diseases (anti-infective and antiparasitic products for systemic use). Additionally, the company offers dietary supplements and electrolyte solutions. Deva Holding also supplies pharmaceuticals targeting major bodily systems such as the urogenital and reproductive systems, blood and hematopoietic organs, the cardiovascular system, musculoskeletal system, nervous system, digestive tract and metabolism, respiratory system, and sensory organs. Furthermore, its offerings include specific drug classes like cephalosporins and penicillin, inhalation therapies, both solid and liquid oncological preparations, and veterinary pharmaceuticals. It also produces active pharmaceutical ingredients (APIs), various sterile dosage forms such as ampoules, liquid and lyophilized vials, and ophthalmic drops, alongside medical ampoules for sterile injectables; cologne is also part of its product line. Beyond its domestic operations, Deva Holding exports its products to approximately 60 nations globally. Established in 1958, the company maintains its headquarters in Istanbul, Turkey, and operates as a subsidiary of Eastpharma S.à R.L.